ANI Pharmaceuticals, Inc. has sent a recommended public offer to acquire Egetis Therapeutics AB (publ), a commercial-stage pharmaceutical company focused on rare diseases.

The offer includes $1.13 per share in cash for Egetis shares, plus cash consideration for outstanding convertible debt and warrants, representing a 27% premium to the 60-day volume-weighted average price.¹ The value of the offer, including outstanding incentive programs, amounts to approximately $560 million, and is adjusted for estimated net proceeds from Egetis’s separate priority review voucher sale, with the deal reflecting an enterprise value of approximately $434 million.^1,3

Egetis’s lead product, Emcitate, was approved by the European Commission on February 12, 2025, and by FDA on September 28, 2026, as the first and only approved treatment for peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency (Allan–Herndon–Dudley syndrome). ANI is estimating the peak sales potential for Emcitate to reach more than $300 million in its approved indication, with durable protection into 2045 supported by new chemical entity exclusivity, orphan drug exclusivity in both the U.S. and Europe, and an Orange Book-listed patent.¹

Dr. Patricia Greenstein, a neurologist and geneticist at Beth Israel Deaconess Medical Center told Pharmaceutical Executive that regulators’ growing acceptance of real-world evidence “can meaningfully shorten the time between scientific discovery and treatment availability” for patients with rare diseases.

“This proposed acquisition further accelerates our transformation with a substantial majority of our revenues expected to be derived from higher margin rare disease products by decade’s end and supports our mission of serving vulnerable patient populations with unmet medical needs,” says Nikhil Lalwani, president and CEO of ANI. “The acquisition of Egetis would strengthen our Rare Disease portfolio and development capabilities. By leveraging our resources and the groundwork laid by Egetis, we estimate peak sales potential for Emcitate of over $300 million in its approved indication coupled with durable protection into 2045, bolstering our long-term growth and profitability profile.”

Egetis’s board unanimously recommends that shareholders accept the offer, noting it enables the company to leverage ANI’s established rare disease platform and U.S. commercialization capabilities to expand patient access to Emcitate.^1,2 Shareholders representing approximately 42% of outstanding shares, including Frazier Life Sciences, Cidro Förvaltning AB, Cetoros AB, Avla Holding AB, The Invus Group, and RegulaPharm AB, have undertaken to accept the offer.¹

The offer is subject to customary closing conditions, including acceptance by shareholders representing at least 90% of outstanding shares and receipt of necessary regulatory approvals, and is financed through cash on hand and new debt financing from JPMorgan Chase Bank, N.A. The acceptance period is expected to begin on or around November 20, 2026, and expire on or around December 18, 2026. Centerview Partners LLC is serving as financial advisor and Advokatfirman Vinge as legal advisor to Egetis.

Egetis Sells Rare Pediatric Disease Priority Review Voucher for $190 Million

Along with the public offer, Egetis Therapeutics together with its wholly owned subsidiary Rare Thyroid Therapeutics International AB (RTTI), announced it has entered a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $190 million.³ Upon closing, former owners of RTTI are entitled to approximately 50% of net proceeds from the voucher as an earn-out tied to Egetis’s 2020 acquisition of Emcitate (tiratricol).³

Egetis was recently granted the voucher on September 28, 2026, in connection with FDA’s approval of Emcitate for peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency.³ The transaction will be subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

Sources

1. ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business ani Pharmaceutical November 5, 2026, https://investor.anipharmaceuticals.com/news-releases/news-release-details/ani-pharmaceuticals-announces-offer-acquire-egetis-therapeutics
2. Statement by the Board of Directors of Egetis Therapeutics in relation to the public cash offer from ANI Pharmaceuticals Egetis Therapeutics November 5, 2026, https://www.egetis.com/news/statement-by-the-board-of-directors-of-egetis-therapeutics-in-relation-to-the-public-cash-offer-from-ani-pharmaceuticals/
3. Egetis Therapeutics Enters Agreement to Sell Priority Review Voucher for USD 190 Million egetis Therapeutics November 4, 2026, https://www.egetis.com/news/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million/